PointState Capital LP Purchases New Stake in Illumina, Inc. $ILMN

Posted by Brian Himes on Aug 27th, 2026

PointState Capital LP purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) in the second quarter, HoldingsChannel reports. The institutional investor purchased 862,210 shares of the life sciences company’s stock, valued at approximately $151,602,000. Illumina accounts for 1.9% of PointState Capital LP’s portfolio, making the stock its 15th largest position.

Several other large investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of Illumina during the 2nd quarter valued at about $3,374,423,000. Primecap Management Co. CA acquired a new stake in Illumina in the second quarter valued at approximately $617,981,000. Jupiter Topco LLC purchased a new stake in shares of Illumina during the second quarter valued at approximately $358,652,000. WCM Investment Management LLC raised its stake in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of Illumina during the second quarter worth $293,846,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $224.84 on Thursday. The firm’s 50 day moving average is $191.66 and its two-hundred day moving average is $154.42. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $227.70. The firm has a market capitalization of $33.95 billion, a P/E ratio of 41.95, a PEG ratio of 3.17 and a beta of 1.45. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ILMN shares. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Leerink Partners increased their price target on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Piper Sandler restated an “overweight” rating and set a $225.00 price objective (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. Stifel Nicolaus lifted their price objective on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Guggenheim upped their target price on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $188.40.

View Our Latest Analysis on ILMN

Insiders Place Their Bets

In other Illumina news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the transaction, the insider owned 20,338 shares in the company, valued at approximately $4,067,600. The trade was a 2.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,874,458 shares of company stock worth $367,996,424 over the last 90 days. Insiders own 2.90% of the company’s stock.

Illumina Profile

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.